Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RXII's Cash to Debt is ranked higher than
75% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. RXII: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RXII' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
50% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -0.66
M-Score: -4.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -15501.56
RXII's Operating margin (%) is ranked lower than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. RXII: -15501.56 )
Ranked among companies with meaningful Operating margin (%) only.
RXII' s Operating margin (%) Range Over the Past 10 Years
Min: -13376.29  Med: -12430.99 Max: -5250.38
Current: -15501.56
-13376.29
-5250.38
Net-margin (%) -15485.94
RXII's Net-margin (%) is ranked lower than
94% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. RXII: -15485.94 )
Ranked among companies with meaningful Net-margin (%) only.
RXII' s Net-margin (%) Range Over the Past 10 Years
Min: -13278.35  Med: -12394.37 Max: -5244.36
Current: -15485.94
-13278.35
-5244.36
ROE (%) -154.89
RXII's ROE (%) is ranked lower than
88% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. RXII: -154.89 )
Ranked among companies with meaningful ROE (%) only.
RXII' s ROE (%) Range Over the Past 10 Years
Min: -336.41  Med: -336.41 Max: -336.41
Current: -154.89
ROA (%) -90.25
RXII's ROA (%) is ranked lower than
85% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. RXII: -90.25 )
Ranked among companies with meaningful ROA (%) only.
RXII' s ROA (%) Range Over the Past 10 Years
Min: -353.55  Med: -203.85 Max: -72.95
Current: -90.25
-353.55
-72.95
ROC (Joel Greenblatt) (%) -5579.87
RXII's ROC (Joel Greenblatt) (%) is ranked lower than
80% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. RXII: -5579.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RXII' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13106.06  Med: -11172.80 Max: -4903.33
Current: -5579.87
-13106.06
-4903.33
» RXII's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

RXII Guru Trades in Q1 2015

Jim Simons 21,200 sh (New)
» More
Q2 2015

RXII Guru Trades in Q2 2015

Jim Simons 507,000 sh (+2291.51%)
» More
Q3 2015

RXII Guru Trades in Q3 2015

Jim Simons 580,000 sh (+14.40%)
» More
Q4 2015

RXII Guru Trades in Q4 2015

Jim Simons 778,800 sh (+34.28%)
» More
» Details

Insider Trades

Latest Guru Trades with RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.65
RXII's P/B is ranked higher than
69% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. RXII: 1.65 )
Ranked among companies with meaningful P/B only.
RXII' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 8.16 Max: 50
Current: 1.65
1.65
50
P/S 222.23
RXII's P/S is ranked lower than
99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. RXII: 222.23 )
Ranked among companies with meaningful P/S only.
RXII' s P/S Range Over the Past 10 Years
Min: 0  Med: 115.00 Max: 357
Current: 222.23
0
357
Current Ratio 7.52
RXII's Current Ratio is ranked higher than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. RXII: 7.52 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 7.31 Max: 11.98
Current: 7.52
0.48
11.98
Quick Ratio 7.52
RXII's Quick Ratio is ranked higher than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. RXII: 7.52 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 7.31 Max: 11.98
Current: 7.52
0.48
11.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.75
RXII's Price/Net Cash is ranked higher than
83% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. RXII: 1.75 )
Ranked among companies with meaningful Price/Net Cash only.
RXII' s Price/Net Cash Range Over the Past 10 Years
Min: 2.31  Med: 9.93 Max: 17.78
Current: 1.75
2.31
17.78
Price/Net Current Asset Value 1.65
RXII's Price/Net Current Asset Value is ranked higher than
84% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. RXII: 1.65 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RXII' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.18  Med: 12.19 Max: 40
Current: 1.65
2.18
40
Price/Tangible Book 1.65
RXII's Price/Tangible Book is ranked higher than
80% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. RXII: 1.65 )
Ranked among companies with meaningful Price/Tangible Book only.
RXII' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.18  Med: 11.77 Max: 35.58
Current: 1.65
2.18
35.58
Earnings Yield (Greenblatt) (%) -152.54
RXII's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. RXII: -152.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RXII' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -152.83  Med: 489.60 Max: 6541.7
Current: -152.54
-152.83
6541.7

More Statistics

Revenue(Mil) $0
EPS $ -0.35
Beta1.70
Short Percentage of Float10.97%
52-Week Range $0.27 - 1.73
Shares Outstanding(Mil)65.35

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -0.23 -0.16 -0.18 -0.22
EPS without NRI($) -0.23 -0.16 -0.18 -0.22

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:44R.Germany,
RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for NAS:RXII

Headlines

Articles On GuruFocus.com
Looking Ahead of Wall Street: RXI Pharmaceuticals, Titan Pharmaceuticals, Micron Technologies Mar 30 2015 
RXi Pharmaceuticals Corp. (RXII) CEO Noah D Beerman buys 10,000 Shares Jul 12 2010 

More From Other Websites
RXi Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference Jan 26 2016
RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for... Dec 21 2015
Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of... Dec 18 2015
RXi Pharmaceuticals to Present at the 8th Annual Biotech Showcase 2016 Dec 14 2015
Galena Biopharma Announces Departure of Chief Financial Officer Dec 11 2015
Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of... Dec 08 2015
RXI PHARMACEUTICALS CORP Financials Dec 08 2015
Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits Dec 04 2015
Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference Nov 30 2015
Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of... Nov 20 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 12 2015
RXi Pharmaceuticals Reports Third Quarter 2015 Financial Results and Business Highlights Nov 12 2015
Q3 2015 Rxi Pharmaceuticals Corp Earnings Release - After Market Close Nov 12 2015
Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its... Nov 09 2015
Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society... Nov 09 2015
Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of... Nov 06 2015
RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for... Nov 05 2015
RXI PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 04 2015
Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical... Oct 30 2015
RXi Pharmaceuticals to Webcast Third Quarter 2015 Financial Results on Thursday, November 12, 2015 Oct 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK